Advertisement

How to Use Central Neuromodulators (CNs) to Help Manage Patients with Disorders of Gut-Brain Interaction (DGBI)

  • W. Harley Sobin
Chapter

Abstract

This article instructs on the use of central neuromodulators to manage patients with chronic functional gastrointestinal disorders that are incompletely responding to dietary changes or peripherally acting gastrointestinal drugs. The use of various psychopharmacologic agents, including SSRIs, SNRIs, TCAs, other antidepressants, and second-generation antipsychotics, is reviewed. The benefit of these agents in managing chronic abdominal pain, nausea, dyspepsia, and altered bowel function is discussed. Case studies are provided. Dosages of the agents and potential side effects are discussed. In addition, a set of questions and answers to drive home salient clinical points is included, as an addendum.

Keywords

Disorders of gut-brain interaction (DGBI) Functional gastrointestinal disorders (FGID) Irritable bowel syndrome (IBS) Central neuromodulators Antidepressants Abdominal pain Dyspepsia Nausea Psychopharmacology 

References

  1. 1.
    Clouse RE, Lustman PJ. Use of psychopharmacological agents for functional gastrointestinal disorders. Gut. 2005;54(9):1332–41.  https://doi.org/10.1136/gut.2004.048884.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Dekel R, Drossman DA, Sperber AD. The use of psychotropic drugs in irritable bowel syndrome. Expert Opin Investig Drugs. 2013;22(3):329–39.  https://doi.org/10.1517/13543784.2013.761205.CrossRefPubMedGoogle Scholar
  3. 3.
    Drossman DA, Tack J, Ford AC, Szigethy E, Törnblom H, Van Oudenhove L. Neuromodulators for functional gastrointestinal disorders (disorders of gut−brain interaction): a Rome foundation working team report. Gastroenterology. 2018;154:1140–1171.e1.  https://doi.org/10.1053/j.gastro.2017.11.279.CrossRefPubMedGoogle Scholar
  4. 4.
    Grover M, Drossman DA. Psychopharmacologic and behavioral treatments for functional gastrointestinal disorders. Gastrointest Endosc Clin N Am. 2009;19(1):151–70.  https://doi.org/10.1016/j.giec.2008.12.001.CrossRefPubMedGoogle Scholar
  5. 5.
    Van Oudenhove L, Levy RL, Crowell MD, et al. Biopsychosocial aspects of functional gastrointestinal disorders: how central and environmental processes contribute to the development and expression of functional gastrointestinal disorders. Gastroenterology. 2016;150(6):1355–1367.e2.  https://doi.org/10.1053/j.gastro.2016.02.027.CrossRefGoogle Scholar
  6. 6.
    Kim SE, Chang L. Overlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms? Neurogastroenterol Motil. 2012;24(10):895–913.  https://doi.org/10.1111/j.1365-2982.2012.01993.x.CrossRefPubMedGoogle Scholar
  7. 7.
    Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med. 2011;62:381–96.  https://doi.org/10.1146/annurev-med-012309-103958.CrossRefPubMedGoogle Scholar
  8. 8.
    Keefer L, Drossman DA, Guthrie E, et al. Centrally mediated disorders of gastrointestinal pain. Gastroenterology. 2016;150(6):1408–19.  https://doi.org/10.1053/j.gastro.2016.02.034.CrossRefGoogle Scholar
  9. 9.
    Stahl SM. Stahl’s essential psychopharmacology. 4th ed. Cambridge: Cambridge University Press; 2013.Google Scholar
  10. 10.
    Schatzberg AF, DeBattista C. Manual of clinical psychopharmacology. Washington, DC: American Psychiatric Publishing; 2015. https://books.google.com/books?hl=en&lr=&id=zT22CAAAQBAJ&pgis=1. Accessed 26 Nov 2015.CrossRefGoogle Scholar
  11. 11.
    Creed F. How do SSRIs help patients with irritable bowel syndrome? Gut. 2006;55(8):1065–7.  https://doi.org/10.1136/gut.2005.086348.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Grover M, Drossman DA. Psychotropic agents in functional gastrointestinal disorders. Curr Opin Pharmacol. 2008;8(6):715–23.  https://doi.org/10.1016/j.coph.2008.07.012.CrossRefPubMedGoogle Scholar
  13. 13.
    Grover M, Drossman DA. Centrally acting therapies for irritable bowel syndrome. Gastroenterol Clin N Am. 2011;40:183–206.  https://doi.org/10.1016/j.gtc.2010.12.003.CrossRefGoogle Scholar
  14. 14.
    Törnblom H, Drossman DA. Centrally targeted pharmacotherapy for chronic abdominal pain. Neurogastroenterol Motil. 2015;27(4):455–67.  https://doi.org/10.1111/nmo.12509.CrossRefPubMedGoogle Scholar
  15. 15.
    Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125(1):19–31. http://www.ncbi.nlm.nih.gov/pubmed/12851867. Accessed 26 Nov 2015.CrossRefGoogle Scholar
  16. 16.
    Tack J, Ly HG, Carbone F, et al. Efficacy of mirtazapine in patients with functional dyspepsia and weight loss. Clin Gastroenterol Hepatol. 2016;14(3):385–392.e4.  https://doi.org/10.1016/j.cgh.2015.09.043.CrossRefPubMedGoogle Scholar
  17. 17.
    Jiang SM, Jia L, Liu J, Shi MM, Xu MZ. Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. World J Gastroenterol. 2016;22:5260–6.  https://doi.org/10.3748/wjg.v22.i22.5260.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Tack J, Janssen P, Masaoka T, Farré R, Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2012;10(11):1239–45.  https://doi.org/10.1016/j.cgh.2012.06.036.CrossRefPubMedGoogle Scholar
  19. 19.
    Coss-Adame E, Erdogan A, Rao SSC. Treatment of esophageal (noncardiac) chest pain: an expert review. Clin Gastroenterol Hepatol. 2014;12(8):1224–45.  https://doi.org/10.1016/j.cgh.2013.08.036.CrossRefPubMedGoogle Scholar
  20. 20.
    Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology. 1987;92(4):1027–36. http://www.ncbi.nlm.nih.gov/pubmed/3549420. Accessed 26 Nov 2015.CrossRefGoogle Scholar
  21. 21.
    Grover M, Dorn SD, Weinland SR, Dalton CB, Gaynes BN, Drossman DA. Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Dig Dis Sci. 2009;54(6):1284–91.  https://doi.org/10.1007/s10620-009-0723-6.CrossRefPubMedGoogle Scholar
  22. 22.
    Sobin WH, Heinrich TW, Drossman DA. Central neuromodulators for treating functional GI disorders: a primer. Am J Gastroenterol. 2017;112:693–702.  https://doi.org/10.1038/ajg.2017.57.CrossRefPubMedGoogle Scholar
  23. 23.
    Sperber AD, Drossman DA. Review article: the functional abdominal pain syndrome. Aliment Pharmacol Ther. 2011;33:514–24.  https://doi.org/10.1111/j.1365-2036.2010.04561.x.CrossRefPubMedGoogle Scholar
  24. 24.
    Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2007;27(1):31–40.  https://doi.org/10.1111/j.1365-2036.2007.03541.x.CrossRefPubMedGoogle Scholar
  25. 25.
    Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(6):811–9.  https://doi.org/10.1038/ajg.2014.82.CrossRefPubMedGoogle Scholar
  26. 26.
    Richter JA, Patrie JT, Richter RP, et al. Bleeding after percutaneous endoscopic gastrostomy is linked to serotonin reuptake inhibitors, not aspirin or clopidogrel. Gastrointest Endosc. 2011;74(1):22–34.e1.  https://doi.org/10.1016/j.gie.2011.03.1258.CrossRefPubMedGoogle Scholar
  27. 27.
    Thiwan S, Drossman DA, Morris CB, et al. Not all side effects associated with tricyclic antidepressant therapy are true side effects. Clin Gastroenterol Hepatol. 2009;7(4):446–51.  https://doi.org/10.1016/j.cgh.2008.11.014.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • W. Harley Sobin
    • 1
  1. 1.Pleasant PrairieUSA

Personalised recommendations